Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Feb;79(5-6):895–902. doi: 10.1038/sj.bjc.6690143

p21WAF1/CIP1expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival

J M Karjalainen 1,2, M Reinikainen 2, V-M Kosma 2,3
PMCID: PMC2362683  PMID: 10070887

Abstract

The expression of p21, p53 and proliferating cell nuclear antigen (PCNA) was analysed by immunohistochemistry in a consecutive series of 369 clinical stage I cutaneous malignant melanoma patients. Correlation of the detected expression levels with each other, with clinicopathological data and with melanoma survival were statistically evaluated. p21 expression was significantly associated with p53 and PCNA expression levels. In addition, high levels of p53 and PCNA were significantly interrelated. Tumour thickness, recurrent disease, high TNM category and older (≥ 55 years) age at diagnosis were inversely associated with p21 expression. Gender, bleeding, tumour thickness, Clark's level of invasion, TNM category and p53 index were all important predictors of both recurrence-free and overall survival of melanoma. In Cox's multivariate analysis including 164 patients with a complete set of data, only high tumour thickness and bleeding predicted poor recurrence-free survival (P= 0.0042 and 0.0087 respectively) or overall survival (P= 0.0147 and 0.0033 respectively). Even though elevated p21 expression may be associated with more favourable prognosis in clinical stage I cutaneous melanoma, our results suggest that cell cycle regulatory effects of p21 can be overcome by some other and stronger, partly yet unknown, mechanisms. 1999 Cancer Research Campaign

Keywords: malignant melanoma, prognosis, p21, p53, proliferation, immunohistochemistry

Full Text

The Full Text of this article is available as a PDF (319.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aaltomaa S., Lipponen P., Papinaho S., Syrjänen K. Proliferating-cell nuclear antigen (PC10) immunolabelling and other proliferation indices as prognostic factors in breast cancer. J Cancer Res Clin Oncol. 1993;119(5):288–294. doi: 10.1007/BF01212727. [DOI] [PubMed] [Google Scholar]
  2. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970 Nov;172(5):902–908. doi: 10.1097/00000658-197011000-00017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Børresen A. L., Hovig E., Smith-Sørensen B., Malkin D., Lystad S., Andersen T. I., Nesland J. M., Isselbacher K. J., Friend S. H. Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8405–8409. doi: 10.1073/pnas.88.19.8405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chen I. T., Smith M. L., O'Connor P. M., Fornace A. J., Jr Direct interaction of Gadd45 with PCNA and evidence for competitive interaction of Gadd45 and p21Waf1/Cip1 with PCNA. Oncogene. 1995 Nov 16;11(10):1931–1937. [PubMed] [Google Scholar]
  5. Clark W. H., Jr, From L., Bernardino E. A., Mihm M. C. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969 Mar;29(3):705–727. [PubMed] [Google Scholar]
  6. Deb S., Jackson C. T., Subler M. A., Martin D. W. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J Virol. 1992 Oct;66(10):6164–6170. doi: 10.1128/jvi.66.10.6164-6170.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. DiGiuseppe J. A., Redston M. S., Yeo C. J., Kern S. E., Hruban R. H. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol. 1995 Oct;147(4):884–888. [PMC free article] [PubMed] [Google Scholar]
  8. Diab S. G., Yu Y. Y., Hilsenbeck S. G., Allred D. C., Elledge R. M. WAF1/CIP1 protein expression in human breast tumors. Breast Cancer Res Treat. 1997 Apr;43(2):99–103. doi: 10.1023/a:1005752829260. [DOI] [PubMed] [Google Scholar]
  9. Doglioni C., Pelosio P., Laurino L., Macri E., Meggiolaro E., Favretti F., Barbareschi M. p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. J Pathol. 1996 Jul;179(3):248–253. doi: 10.1002/(SICI)1096-9896(199607)179:3<248::AID-PATH571>3.0.CO;2-6. [DOI] [PubMed] [Google Scholar]
  10. Flores-Rozas H., Kelman Z., Dean F. B., Pan Z. Q., Harper J. W., Elledge S. J., O'Donnell M., Hurwitz J. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8655–8659. doi: 10.1073/pnas.91.18.8655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gelsleichter L., Gown A. M., Zarbo R. J., Wang E., Coltrera M. D. p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors. Mod Pathol. 1995 Jun;8(5):530–535. [PubMed] [Google Scholar]
  12. Harada N., Gansauge S., Gansauge F., Gause H., Shimoyama S., Imaizumi T., Mattfeld T., Schoenberg M. H., Beger H. G. Nuclear accumulation of p53 correlates significantly with clinical features and inversely with the expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in pancreatic cancer. Br J Cancer. 1997;76(3):299–305. doi: 10.1038/bjc.1997.382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Harper J. W., Adami G. R., Wei N., Keyomarsi K., Elledge S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993 Nov 19;75(4):805–816. doi: 10.1016/0092-8674(93)90499-g. [DOI] [PubMed] [Google Scholar]
  14. Hiyama H., Iavarone A., LaBaer J., Reeves S. A. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression. Oncogene. 1997 May 29;14(21):2533–2542. doi: 10.1038/sj.onc.1201080. [DOI] [PubMed] [Google Scholar]
  15. Jiang H., Lin J., Su Z. Z., Herlyn M., Kerbel R. S., Weissman B. E., Welch D. R., Fisher P. B. The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. Oncogene. 1995 May 4;10(9):1855–1864. [PubMed] [Google Scholar]
  16. Jung J. M., Bruner J. M., Ruan S., Langford L. A., Kyritsis A. P., Kobayashi T., Levin V. A., Zhang W. Increased levels of p21WAF1/Cip1 in human brain tumors. Oncogene. 1995 Nov 16;11(10):2021–2028. [PubMed] [Google Scholar]
  17. Lassam N. J., From L., Kahn H. J. Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res. 1993 May 15;53(10 Suppl):2235–2238. [PubMed] [Google Scholar]
  18. Maelandsmo G. M., Holm R., Fodstad O., Kerbel R. S., Flørenes V. A. Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions. Am J Pathol. 1996 Dec;149(6):1813–1822. [PMC free article] [PubMed] [Google Scholar]
  19. Melhem M. F., Law J. C., el-Ashmawy L., Johnson J. T., Landreneau R. J., Srivastava S., Whiteside T. L. Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. Am J Pathol. 1995 May;146(5):1170–1177. [PMC free article] [PubMed] [Google Scholar]
  20. Michieli P., Chedid M., Lin D., Pierce J. H., Mercer W. E., Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 1994 Jul 1;54(13):3391–3395. [PubMed] [Google Scholar]
  21. Moll U. M., Riou G., Levine A. J. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7262–7266. doi: 10.1073/pnas.89.15.7262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Nadal A., Jares P., Cazorla M., Fernández P. L., Sanjuan X., Hernandez L., Pinyol M., Aldea M., Mallofré C., Muntané J. p21WAF1/Cip1 expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx. J Pathol. 1997 Oct;183(2):156–163. doi: 10.1002/(SICI)1096-9896(199710)183:2<156::AID-PATH908>3.0.CO;2-O. [DOI] [PubMed] [Google Scholar]
  23. Naresh K. N., O'Conor G. T., Soman C. S., Johnson J., Advani S. H., Magrath I. T., Bhatia K. G. A study of p53 protein, proliferating cell nuclear antigen, and p21 in Hodgkin's disease at presentation and relapse. Hum Pathol. 1997 May;28(5):549–555. doi: 10.1016/s0046-8177(97)90077-0. [DOI] [PubMed] [Google Scholar]
  24. Nishio M., Koshikawa T., Kuroishi T., Suyama M., Uchida K., Takagi Y., Washimi O., Sugiura T., Ariyoshi Y., Takahashi T. Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J Clin Oncol. 1996 Feb;14(2):497–502. doi: 10.1200/JCO.1996.14.2.497. [DOI] [PubMed] [Google Scholar]
  25. Ory K., Legros Y., Auguin C., Soussi T. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J. 1994 Aug 1;13(15):3496–3504. doi: 10.1002/j.1460-2075.1994.tb06656.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Podust V. N., Podust L. M., Goubin F., Ducommun B., Hübscher U. Mechanism of inhibition of proliferating cell nuclear antigen-dependent DNA synthesis by the cyclin-dependent kinase inhibitor p21. Biochemistry. 1995 Jul 11;34(27):8869–8875. doi: 10.1021/bi00027a039. [DOI] [PubMed] [Google Scholar]
  27. Ro Y. S., Cooper P. N., Lee J. A., Quinn A. G., Harrison D., Lane D., Horne C. H., Rees J. L., Angus B. p53 protein expression in benign and malignant skin tumours. Br J Dermatol. 1993 Mar;128(3):237–241. doi: 10.1111/j.1365-2133.1993.tb00164.x. [DOI] [PubMed] [Google Scholar]
  28. Sparrow L. E., English D. R., Heenan P. J., Dawkins H. J., Taran J. Prognostic significance of p53 over-expression in thin melanomas. Melanoma Res. 1995 Dec;5(6):387–392. doi: 10.1097/00008390-199512000-00001. [DOI] [PubMed] [Google Scholar]
  29. Talve L., Kainu J., Collan Y., Ekfors T. Immunohistochemical expression of p53 protein, mitotic index and nuclear morphometry in primary malignant melanoma of the skin. Pathol Res Pract. 1996 Aug;192(8):825–833. doi: 10.1016/S0344-0338(96)80056-2. [DOI] [PubMed] [Google Scholar]
  30. Tron V. A., Tang L., Yong W. P., Trotter M. J. Differentiation-associated overexpression of the cyclin-dependent kinase inhibitor p21waf-1 in human cutaneous squamous cell carcinoma. Am J Pathol. 1996 Oct;149(4):1139–1146. [PMC free article] [PubMed] [Google Scholar]
  31. Trotter M. J., Tang L., Tron V. A. Overexpression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in human cutaneous malignant melanoma. J Cutan Pathol. 1997 May;24(5):265–271. doi: 10.1111/j.1600-0560.1997.tb00790.x. [DOI] [PubMed] [Google Scholar]
  32. Vidal M. J., Loganzo F., Jr, de Oliveira A. R., Hayward N. K., Albino A. P. Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas. Melanoma Res. 1995 Aug;5(4):243–250. doi: 10.1097/00008390-199508000-00006. [DOI] [PubMed] [Google Scholar]
  33. Vogt T., Zipperer K. H., Vogt A., Hölzel D., Landthaler M., Stolz W. p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. Histopathology. 1997 Jan;30(1):57–63. doi: 10.1046/j.1365-2559.1996.d01-558.x. [DOI] [PubMed] [Google Scholar]
  34. Vojtesek B., Bártek J., Midgley C. A., Lane D. P. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods. 1992 Jul 6;151(1-2):237–244. doi: 10.1016/0022-1759(92)90122-a. [DOI] [PubMed] [Google Scholar]
  35. Waga S., Hannon G. J., Beach D., Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 1994 Jun 16;369(6481):574–578. doi: 10.1038/369574a0. [DOI] [PubMed] [Google Scholar]
  36. Wakasugi E., Kobayashi T., Tamaki Y., Ito Y., Miyashiro I., Komoike Y., Takeda T., Shin E., Takatsuka Y., Kikkawa N. p21(Waf1/Cip1) and p53 protein expression in breast cancer. Am J Clin Pathol. 1997 Jun;107(6):684–691. doi: 10.1093/ajcp/107.6.684. [DOI] [PubMed] [Google Scholar]
  37. Weiss J., Heine M., Körner B., Pilch H., Jung E. G. Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications. Br J Dermatol. 1995 Jul;133(1):23–31. doi: 10.1111/j.1365-2133.1995.tb02487.x. [DOI] [PubMed] [Google Scholar]
  38. Wynford-Thomas D. P53 in tumour pathology: can we trust immunocytochemistry? J Pathol. 1992 Apr;166(4):329–330. doi: 10.1002/path.1711660402. [DOI] [PubMed] [Google Scholar]
  39. Yamamoto M., Takahashi H., Saitoh K., Horikoshi T., Takahashi M. Expression of the p53 protein in malignant melanomas as a prognostic indicator. Arch Dermatol Res. 1995;287(2):146–151. doi: 10.1007/BF01262323. [DOI] [PubMed] [Google Scholar]
  40. Yasui W., Akama Y., Kuniyasu H., Yokozaki H., Semba S., Shimamoto F., Tahara E. Expression of cyclin-dependent kinase inhibitor p21WAF1/CIP1 in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity. J Pathol. 1996 Oct;180(2):122–128. doi: 10.1002/(SICI)1096-9896(199610)180:2<122::AID-PATH647>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  41. Zeng Y. X., Somasundaram K., el-Deiry W. S. AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nat Genet. 1997 Jan;15(1):78–82. doi: 10.1038/ng0197-78. [DOI] [PubMed] [Google Scholar]
  42. Zeng Y. X., el-Deiry W. S. Regulation of p21WAF1/CIP1 expression by p53-independent pathways. Oncogene. 1996 Apr 4;12(7):1557–1564. [PubMed] [Google Scholar]
  43. el-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993 Nov 19;75(4):817–825. doi: 10.1016/0092-8674(93)90500-p. [DOI] [PubMed] [Google Scholar]
  44. el-Deiry W. S., Tokino T., Waldman T., Oliner J. D., Velculescu V. E., Burrell M., Hill D. E., Healy E., Rees J. L., Hamilton S. R. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res. 1995 Jul 1;55(13):2910–2919. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES